Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin C Welch

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
Allergy and Asthma Proceedings|September 3, 2021
Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitisGayatri B Patel, Elizabeth A Kudlaty, Amina Guo, et al.
Immunity, Inflammation and Disease|May 6, 2017
Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polypsJulie A Poposki, Aiko I Klingler, Bruce K Tan, et al.
The Journal of Allergy and Clinical Immunology|January 9, 2023
Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polypsBao-Feng Wang, Ping-Ping Cao, James E Norton, et al.
The Journal of Allergy and Clinical Immunology|October 28, 2017
IL-10, TGF-β, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cellsNoriko Ogasawara, Julie A Poposki, Aiko I Klingler, et al.
The Journal of Allergy and Clinical Immunology|October 9, 2025
Effects of type 3 and neutrophilic inflammation on type 2 chronic rhinosinusitis with nasal polypsAiko Oka, Aiko I Klingler, Masanori Kidoguchi, et al.
International Forum of Allergy & Rhinology|April 1, 2022
Use of intraoperative frontal sinus mometasone-eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polypsAlexander L Schneider, Samuel D Racette, Anthony K Kang, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Validation of a risk predictor score for early polyp recurrence in CRSwNPJunqin Bai, Lutfiyya N Muhammad, Aditi Agarwal, et al.
The Journal of Allergy and Clinical Immunology|April 9, 2026
Heterogeneity and Clinical Relevance of Group 2 Innate Lymphoid Cells Subsets in Nasal PolypsMasanori Kidoguchi, Naruhito Iwasaki, Julie A Poposki, et al.
The Journal of Allergy and Clinical Immunology|May 7, 2020
Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory diseaseWhitney W Stevens, Anna G Staudacher, Kathryn E Hulse, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2016
Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitisGriet A Van Roey, Christopher C Vanison, Jeffanie Wu, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
Allergy and Asthma Proceedings|September 3, 2021
Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitisGayatri B Patel, Elizabeth A Kudlaty, Amina Guo, et al.
Immunity, Inflammation and Disease|May 6, 2017
Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polypsJulie A Poposki, Aiko I Klingler, Bruce K Tan, et al.
The Journal of Allergy and Clinical Immunology|January 9, 2023
Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polypsBao-Feng Wang, Ping-Ping Cao, James E Norton, et al.
The Journal of Allergy and Clinical Immunology|October 28, 2017
IL-10, TGF-β, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cellsNoriko Ogasawara, Julie A Poposki, Aiko I Klingler, et al.
The Journal of Allergy and Clinical Immunology|October 9, 2025
Effects of type 3 and neutrophilic inflammation on type 2 chronic rhinosinusitis with nasal polypsAiko Oka, Aiko I Klingler, Masanori Kidoguchi, et al.
International Forum of Allergy & Rhinology|April 1, 2022
Use of intraoperative frontal sinus mometasone-eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polypsAlexander L Schneider, Samuel D Racette, Anthony K Kang, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Validation of a risk predictor score for early polyp recurrence in CRSwNPJunqin Bai, Lutfiyya N Muhammad, Aditi Agarwal, et al.
The Journal of Allergy and Clinical Immunology|April 9, 2026
Heterogeneity and Clinical Relevance of Group 2 Innate Lymphoid Cells Subsets in Nasal PolypsMasanori Kidoguchi, Naruhito Iwasaki, Julie A Poposki, et al.
The Journal of Allergy and Clinical Immunology|May 7, 2020
Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory diseaseWhitney W Stevens, Anna G Staudacher, Kathryn E Hulse, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2016
Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitisGriet A Van Roey, Christopher C Vanison, Jeffanie Wu, et al.
Pageof 10